RE:RE:RE:Conference CallWith regard to enrollment in a phase 3 study or a transitional study that leads to a phase 3, i think we are looking at 8 months for the pancreatic trial. We'll know early the progression free survival results for Pancreatic disease since death from prognosis advances rapidly. And ONC will get Accelerated Approval for this one. Markets will see a clear timeline to a cash rainbow for pela as a pancreatic therapeutic.
I know ONC is investigating additional treatment combinations for Pancreatic. I assume to improve on efficacy which is outstanding, and i would think to find a less expensive solution apart from ICI combo? Someone might want to comment on this.
We must wait three months to hear intentions for the Breast Cancer trial design and timing. Its definitely going to be a phase 2 with phase 3 potential in probably a few years. Market size, timing and risk for Breast Cancer took a beating yesterday. And speakers discussion yesterday reflected the conundrum.
ONCs share price we all know has been totally disconnected from the pela technology and opportunity. Even with demotion of the Breast Cancer, ONC share price is still disconnected and perhaps now even more so. Yesterday provided a clarity to market for Pancreatic beginning with enrollment in the near term. ONC is dramatically under priced for this reality and the cashflows, partnership and potential sale it brings.